BioNanotechnology Summer Institute 2014 - Poster Session 08/04/14
Sep 5, 2023
Okay, I'm Atoa Ariyathinyopis. I've been working with the nanolab, nanotech, in Thailand and what I'm doing is the synthesis of molybdenum dioxide to catalyze the production of octanoic acid.
What I do is I synthesize catalysts using simple terms such as hydrothermal. It's a hot one pot synthesis which makes it very easy to control.
And there are other ways you can synthesize molybdenum dioxide which is through impact but that's something else.
So there are three ways that octanoic could have been. Through the oxygenation process, it could have gone through hydrogenation, decarboxylation, or decarbonylation.
It's not on there but it's supposed to. So the reason why I chose molybdenum dioxide is because it has a very similar structure to molybdenum sulfide which is a traditional catalyst.
We have been using molybdenum sulfide in our labs for a very long time. It has no chance of sulfur contamination. The reaction to produce molybdenum dioxide is very simple.
The one pot synthesis we put in ammonium molybdate tetrahydrate with vitamin C. This is a basic setup. The product that we got is in powder form. I extract it through centrifuge.
So going through XRD, I know that comparing the result with other database, it is indeed molybdenum dioxide and I vary the hours I use to produce the molybdenum dioxide to 4 hours, 7 hours, 3 hours, and even 1 hour.
It seems like the lower the time we use, the less surface area we have. So by increasing the time, we can see that the greater the surface area, that's more efficient as it's a catalyst.
After getting molybdenum dioxide, I put it into reaction with octanoic acid and this is what we got. To be a good catalyst, the reaction should be reusable which means it should be able to extract out of the octanoic acid product.
In this case, it pretty much got diffused into the octanoic acid making the product black.
I put the product into GC and what I got wasn't what I expected. I put the peak one is hexane and this one is octanoic acid and these are all the unknowns that when looking through the database, I couldn't find what it was.
This is octane, what I was looking for. It's an ongoing research and I'll conduct some more experiments.
My name is Sandra Arias. This is my poster. I'm presenting a work titled Bioactive Hydrogel. I'm based on bacterial nanocellulose for supporting neurovascular aneurysm and neck closure.
In this work, we did some mechanical testing of the hydrogel and we found that this material is very close to the properties of the arterial wall. It's very suitable for this kind of application.
Hi, I'm Kimberly Kaydotta from West Virginia University. I'm here to talk about our Ren at WVU and Nanosafe graduate fellowships. Both of these graduate fellowships are in the area of nanotechnology.
Our Ren at WVU is an IGRT program and it focuses in nanotoxicology. Our Nanosafe program focuses on nanobiosensing. Both of these programs have graduate students and both groups are working together synergistically in the area of nanotechnology.
Our IGRT program specifically focuses in nanotoxicology. We have about 14 graduate students in our Ren at WVU program and we have about 13 students in our Nanosafe program.
The groups work together on interdisciplinary research, science communications, an innovation challenge, and team building activities.
In terms of our interdisciplinary research, each student has two advisors. In many cases, those advisors are from widely, vastly different programs. For instance, physics and pharmacy, or chemistry and engineering, chemical engineering and pharmacy.
We have a variety of researchers working together throughout West Virginia University on these projects and helping these students.
In terms of science communications, one of our programs that we're working on with our Nanosafe and IGRT programs is called Science on Tabs. The students are organizing lectures for the community.
Our next upcoming lecture is in art conservation. An expert in art conservation will present at a local brewery. They're encouraged to have a social atmosphere and present to the wide variety community.
Our last Science on Tab had about 75 people from the public, so it's a well-attended event. We also work very heavily with outreach activities throughout West Virginia, probably about 12 of those per year.
In terms of our innovation challenge, students at the IGRT and Nanosafe program have the opportunity to create a business plan and gain about $15,000 seed money for their programs.
Hi, my name's Matthew Martin, and this poster that I'm presenting is based on some experiments I did when I was a post-doc at the National Institute of Standards and Technology.
Currently, I'm an assistant professor of physics at Califa University in the United Arab Emirates, and this work was motivated because there's a lot of interest in the stability of nanoparticles in environmental, biological conditions.
And then what I do is I stick it in an x-ray beam as it's dissolving in acid. And what you see is if you add just a little bit of acid, you don't change the solution that much. Your measurements don't change over almost eight, nine hours.
And so it becomes very challenging to separate the loss of material due to aggregation, dissolution, and sedimentation. But if you're careful, you can look at simple quantities, like the diameter of a particle.
And so this leads us to this overall model, where if you add just a little bit of acid, the particles, due to fluctuations in solution chemistry, they might lose atoms and dissolve.
So my research is on making a very sensitive mechanism that picks up the force that the cell produces when you add a drug. This process consists on making a polyacrylamide gel, and it makes a very, very thin gel with fluorescent bits.
When you see the gel after functionalization of the gel, the cell, it's going to pull on the gel along with the bits. So by knowing where the bit is and where the bit was, you're able to quantify the displacement of the bit.
Because you know the specifics of the gel, so you know the stiffness, which is the Young's modulus, and the Poisson's ratio, you can quantify the strain energy and the force that the gel had to produce to move that bit.
My several hiccups that we have found to be able to make this process a lot more specific is increasing the bit concentration. That way you can pick up small changes in the force and making the bits a lot smaller.
Because at least the bits we're using right now are 3.2 micrometers, when on average a cell is about 10 micrometers. So the smaller the gel, the smaller changes you're going to be able to pick up.
Hi, my name is Nicholas Calvo. I'll be starting my first year as a PhD student at the University of Florida in the Gator Bay Laboratory.
My poster here is on dynamic cell culture of 3D cardiac microtissues. So basically, there's predicted to be a million incidents of myocardial infarction or heart attacks in the next year in the U.S., and 30% of which are reoccurring incidents.
And that amounts to about $200 billion a year in direct and indirect costs. So this is kind of an important clinical diagnosis thing.
So we're trying to use induced pluripotent stem cells that are patient-specific for people with cardiovascular disease to analyze how stem cell therapy, cell and gene therapy treatments can help wound healing in these areas.
So to do that, we've started developing these mechanical systems, first of which is a low-throughput stretching system that fits perfectly in a cell culture plate for an in vitro microscope.
It just kind of gives you a real-time testing platform in an inverted microscope.
These high-throughput stretching systems utilize vacuum to perform their stretching.
So you can see here that there's a thin silicone membrane here that your cells are plated on, and when your vacuum's pulled around the post, you get stretching of the cells biaxially.
So using that, they're in a 12-well and 96-well plate fashion, so you can do very high-throughput analysis of cells biochemically and functionally using this system here.
So we're also trying to implement these 3D constructs for stretching.
Everything in the body is three-dimensional, so by embedding cells in these 3D collagen constructs and stretching them, you get a better idea of how 3D strain affects cell morphology, physiology, and ultimately have a better in vitro model.
And then also we have these synergistic effects.
Basically, this is a program when you upload a video, it gives you a plot of your time versus contractile movement.
But basically, all contractile measurements for myocardial cells.
And you see you can basically measure that out using this program.
And ultimately future work, since we just started this summer, we're kind of building up all our mechanical suites that we're going to use as our testing platforms for these cells.
My name is Emily Despo, and I work with magnetic iron oxide nanoparticles for improved cancer drug delivery and cancer diagnosis.
So one of the main problems with cancer chemotherapy drugs is that they attack all rapidly dividing cells in your body.
So this means that when you take a chemotherapy drug, it attacks the lining of your stomach causing nausea, your hair follicles causing hair loss, as well as the cancer itself.
So one way we hope to fix this problem, well there's two major ways to fix this problem really, and one is to improve the selectivity of the drugs so that they affect only the cancer cells.
That would be something more like taking an antibiotic, which hopefully only kills the bacteria and not you, or to physically target these particles or the drugs to a tumor.
So with our project, we're primarily looking at that first option, which is to make something that acts selectively on cancer cells.
So one way to do that is to find something that's unique to the cancer cells, some sort of feature that they have.
And so most cancer cells arise from normal healthy tissue, which means they have a lot of the same features, sometimes a little bit more, a little bit less.
It makes it very hard to find specific reasons or specific ways to target those cells.
So there's a protein called survivin that's anti-apoptotic, and this protein is highly expressed in cancer cells across almost all kinds of cancer.
And it's found at very, very low or negligible levels in healthy tissue, making it an ideal target for something that only acts on cancer cells, found across many types of cancer.
And in vitro, anti-sense agents have been used to reduce this significant amount, reduce survivin expression by 30-70% depending on the cell culture type.
And with this reduction in viability, you also get increased sensitivity to chemotherapy, radiation, so different treatments.
And even alone, you can get reduced viability because the cell is more sensitive to the apoptotic signals from itself and the environment.
The problem is that when you try to translate this in vitro success to an in vivo system, DNA is rapidly cleared.
So any sort of DNA or anti-sense agent you introduce into your body will be cleared very rapidly, just like if you got a virus and you don't want it to go very far.
So one way to improve this is to use a delivery platform.
So in our case, we've picked superparamagnetic iron oxide nanoparticles, or SPIONs.
And superparamagnetism is a very important feature.
It means that they're not magnetic until they're in a magnetic field.
We can use them for something like an MRI, but up until we need them for that particular feature, they don't stick to each other in the bottle, in the needles, or in your blood.
So we start with this iron oxide nanoparticle, and it's coated in oleic acid.
And then we coat it with a modified polyacrylic acid polymer.
And this has hydrophobic oxylamines that will interact with this oleic acid, and it leaves carboxylic acid groups on the outside of the particle.
We can functionalize these carboxylic acid groups using EDC to form an amide linkage with any sort of amine-modified substance.
So things like DNA, RNA, or antibodies.
So in our particular case, we're interested in antisense to survive it.
So the protein that I've just described.
So an antisense agent is a 20-base single-stranded DNA that we attach and do the whole thing.
And so we start with it, the oleic acid coat of particles, which we then characterize to make sure that they're all the same size.
We found that this is a very uniform synthesis.
They're approximately 7 nanometers.
This is very reproducible.
This is dynamic light scattering.
We've shown that with the oleic acid coating, they're approximately 11 nanometers.
And we don't have the size.
This part of the coating is a little bit less consistent, so I don't have the exact size range.
But we also want to know if these went into cells.
So we used a fluorescent tag on the DNA label and incubated A549 lung adenocarcinoma cells with our fluorescently labeled particles.
And at 24 hours, the particles were seen as red, the nucleus as blue, and the particles were seen with a green fluorescein.
So all these areas of yellow, which you can see particularly well surrounding the nucleus of the cell, are areas where the particles have co-localized with the endosome.
It means that they are being taken up by the cell, but it might also lead you to question whether or not they're able to have an effect.
But just to make sure that these particles that we were seeing were, in fact, inside the cells and not on the cells, even though we've washed them,
we have concocal 3D rendering, so it's the same red for the cell to cytoplasm, and green for the particles.
Looking at the series of cutaways, you can see that the particles are, in fact, inside the cell.
And there's where the nucleus was.
It didn't get rendered.
And you can see that they're not in the nucleus, which is good.
They need to be in the cytoplasm to have their effect.
So we did viability assays just to get an idea of how effective these particles were.
And using a non-targeting controlled sequence of the same length of our antisense sequence as our control,
we have no change in metabolic viability after a 48-hour incubation with these particles.
However, with our antisense agent, the viability decreases linearly in concentration of the antisense agent.
So this shows that the effects are coming from the antisense agent itself.
And even though the effect isn't as significant on the graph as you might expect,
it's because we have strong batch dependence on each time we add the DNA to the particles.
So within a particular batch, these results are actually very, very focused and close together.
So we're going to work a little bit on some of that consistency.
The other ways we looked at their effects on cells was to look at LDH release.
And LDH, lactate dehydrogenase, is an enzyme found inside of the cell, and it's released when the cell lyses.
So this is a way of measuring membrane damage, if it's leaking, if the cells have lice.
But LDH has a half-life of approximately nine hours, which means we did this assay at 48 hours.
If the cells died more than nine hours prior to our experiment,
there was probably not much LDH and not many cells in our experimental wells.
If you have no cells, if you've killed them all pretty early with a growth restriction of some sort,
you can get either negative LDH release compared to a healthy control because there are less cells,
or your LDH release isn't necessarily where you would expect because the cell number is different.
So one of the things that you can see off of this, though,
is that the non-targeting control doesn't change the viability or lay it off.
While the LDH release, which would be increased cell death or cell lysis,
increases with increasing concentrations of our spions, with the antisense agent.
One of the interesting things is that the way we did this was we used the same wells
for both the LDH release and the viability studies.
We took supernatant off to test the LDH, which means that we can come up with a direct correlation
between the LDH release, which is cell lysis in a well, at that time point,
and the viability at the same time point, which, again, gave us an interesting linear correlation.
The number of cells viability increasing as DNA concentration increased.
So at this point, even though these are sort of preliminary studies on this topic,
we've shown that we can reproducibly make these particles.
We get the 7 nanometer iron oxide core.
We've also started characterizing the magnetic properties of this
to see how it might be useful in an MRI.
We've shown that our spions are taken up by cells, presumably by endosomes,
and they don't enter the nucleus, which means they're in the cytoplasm
where they can have their effect.
But we don't actually see any changes in viability at the 24-hour incubation,
which is why it's not shown right here.
But we do see significant changes after a 48-hour incubation,
and they're strongly dose-dependent.
So we want to work a little bit on getting the consistency of our batches
so that they always give us the same results.
We're making one large batch so we can test them all for the same results.
We also want to assess the changes in surviving expressions
throughout the cell's life cycle, or the cell's exposure to these antisense spions.
Or the non-targeting control.
And see how that correlates to the viability studies.
And we've started doing this, and our initial studies have actually shown
that the surviving expression is decreasing with our antisense agent.
We didn't have enough data to show significance on the poster.
And then we want to see if we can use these particles to sensitize our cells
to chemotherapy agents like cisplatin.
Cisplatin have done initial dosing studies,
and that's because surviving is anti-apoptotic,
which means that its removal by itself does not inherently affect the cell.
There still needs to be some sort of stimulus,
whether intrinsic or extrinsic.
So if we can stimulate this with cisplatin,
we might see even greater cell death.
And then we want to see how selective this is,
because at this point our construct is really only therapeutically targeting these cells,
and there's still a need for physically targeting these cells
for improved MRI contrast enhancement,
improved drug delivery capacity.
And we have a couple of ideas for how we could possibly target this,
actually using the surviving expression of the cell as sort of a marker,
because of the way that cisplatin works.
And so this right here is just sort of the overview of this project.
And we've done, right now we've focused primarily on this characterization aspect,
reports a little bit on the composition.
And we've started looking at the effects on cell function.
And then hopefully, ultimately,
we could start working on an MRI contrast agent,
looking at these, their drug loading abilities,
their plasma-protein interactions,
and their bio-distribution,
probably in mice actually in the next couple of months.
Transcribed by https://otter.ai

